Clostridium difficile infection and inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 47, Issue 8, 2013, Pages 666-671

  Reddy, Sheela S ^a   Brandt, Lawrence J ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; Colitis; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CIPROFLOXACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; ENEMA; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISONE; PROBIOTIC AGENT; RIFAXIMIN; VANCOMYCIN;

ACTINOBACTERIA; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIMICROBIAL THERAPY; BACILLUS; BACTEROIDETES; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; ENTERITIS; ENZYME IMMUNOASSAY; FAECALIBACTERIUM PRAUSNITZII; FECES CULTURE; FECES MICROFLORA; FIRMICUTES; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTESTINE FLORA; LACHNOSPIRACEAE; LACTOBACILLUS; LEUKOCYTOSIS; LOW DRUG DOSE; MICROBIOME; MORBIDITY; MORTALITY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEOBACTERIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTAL TUBE; REVIEW; SACCHAROMYCES BOULARDII; SENSITIVITY AND SPECIFICITY; TERTIARY HEALTH CARE; ULCERATIVE COLITIS;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84883251271     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31828b288a     Document Type: Review

References (66)

1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006;12: 409-415.
2. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5: 345-351.
3. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5: 339-344.
4. Bossuyt P, Verhaegen J, Van Assche G, et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009;3: 4-7.
5. Blossom DB, McDonald LC. The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis. 2007; 45: 222-227.
6. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008;14: 1432-1442.
7. Singh S, Graff LA, Bernstein CN. Do NSAIDs antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol. 2009;104: 1298-1313.
8. LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980;1: 381-383.
9. Bolton RP, Read AE. Clostridium difficile in toxic megacolon complicating acute inflammatory bowel disease. Br Med J (Clin Res Ed). 1982;285: 475-476.
10. Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981;80: 863-865.
11. Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand J Gastroenterol. 1983;18: 61-64.
12. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57: 205-210.
13. Jen MH, Saxena S, Bottle A, et al. Increased health burden associated with Clostridium difficile diarrhea in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33: 1322-1331.
14. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30: 253-264.
15. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol. 2010;105: 2040-2049.
16. Kariv R, Navaneethan U, Venkatesh P, et al. Impact of C. difficile infection in patients with ulcerative colitis. J Crohns Colitis. 2011;5: 34-40.
17. Meyer AM, Ramzan NN, Loftus EV, et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38: 772-775.
18. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: 50-55.
19. Ananthakrishnan AN, McGinley E, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17: 976-983.
20. Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010;4: 194-198.
21. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficileinfections. Am J Gastroenterol. (publication pending).
22. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16: 775-778.
23. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and Infectious Disease Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31: 431-455.
24. Tremaine WJ. Inflammatory bowel disease and Clostridium difficile-associated diarrhea: a growing problem. Clin Gastroenterol Hepatol. 2001;5: 310-311.
25. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin J Gastroenterol Hepatol. 2009;7: 981-987.
26. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38: 475-483.
27. Damman CJ, Miller SI, Surawicz CM, et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107: 1452-1459.
28. Frank DN, St Amand AI, Feldman RA, et al. Molecular phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc Natl Acad Sci USA. 2007;104: 13780-13785.
29. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol. 2012;1(suppl): 15-21.
30. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105: 16731-16736.
31. Johnston BC, Ma SSY, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 2012; 157: 878-888.
32. Na X, Kelly. C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol. 2011;45:S154-S158.
33. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: the use of high dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31: 1012-1017.
34. Wullt M, Hagslatt M-LJ, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficileassociated diarrhea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35: 365-367.
35. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101: 812-822.
36. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. JAMA. 2012;307: 1959-1969.
37. Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44: 854-859.
38. Paterson DL, Irdell J, Whitby M. Putting back the bugs: bacterial treatment relieves chronic diarrhea. Med J Aust. 1994;160: 232-233.
39. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010;44: 562-566.
40. Rohlke F, Surawucz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol. 2010;44: 567-570.
41. Lund-Tonnesen S, Berstad A, Schreiner A, et al. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen. 1998;118: 1027-1030.
42. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36: 580-585.
43. Flotterod O, Hopen G. Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis. Tidsskr Nor Laegeforen. 1991;111: 1345-1346.
44. Garborg K, Waagsbo B, Stallemo A, et al. Results of fecal donor instillation therapy for recurrent Clostridium difficileassociated diarrhea. Scand J Infect Dis. 2010;42: 857-861.
45. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012; 36: 503-516.
46. Watson JB, Habr F, Kelly C. First reported complication of fecal microbiota transplant: ulcerative colitis flare after FMT for relapsing Clostridium difficile infection. Gastroenterology. 2012;142:S540.
47. Brandt LJ, Aroniadis OC. Long-term follow-up study of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). Am J Gastroenterol. 2012;107(suppl 1): 1626, S657.
48. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009;104: 1162-1169.
49. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin of metronidazole: a randomized, placebocontrolled trial. Ann Intern Med. 1992;117: 297-302.
50. Hsu J, Abad C, Dinh M, et al. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol. 2010;105: 2327-2339.
51. Chiplunker A, Ananthakrishnan AN, Beaulieu DB, et al. Long term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology. 2009;136(suppl 1):S1145.
52. Ananthakrishnan AN, Guzman-Perez R, Gainer V, et al. Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35: 789-795.
53. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: 1443-1450.
54. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci. 2010;55: 415-420.
55. Navaneethan U, Mukewar S, Venkatesh PG, et al. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6: 330-336.
56. Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012;36: 1032-1039.
57. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology. 2006;130: 1311-1316.
58. Issa M, Weber LR, Brandenburg H, et al. Rifaximin and treatment of recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Am J Gastroenterol. 2006; 101:S469.
59. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea, and colitis. World J Gastroenterol. 2009;15: 1554-1580.
60. Lundeen SJ, Otterson MF, Binion DG, et al. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg. 2007;11: 138-142.
61. Wilcox MH, Fawley WN, Settle CD, et al. Recurrence of symptoms in Clostridium difficile infection - relapse or reinfection? J Hosp Infect. 1998;38: 93-100.
62. Tjandra JJ, Street A, Thomas RJ, et al. Fatal Clostridium difficile infection of the small bowel after complex colorectal surgery. ANZ J Surg. 2001;71: 500-503.
63. Holmer C, Zurbuchen U, Siegmund B, et al. Clostridium difficile infection of the small bowel - two case reports with a literature survey. Int J Colorectal Dis. 2011;26: 245-251.
64. Shen B, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6: 782-788.
65. Shen B, Goldblum JR, Hull TL, et al. Clostridium difficileassociated pouchitis. Dig Dis Sci. 2006;51: 2361-2364.
66. Mann SD, Pitt J, Springall RG, et al. Clostridium difficile infection - an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003;46: 267-270.